Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Adapted from data in the NEJM 1 | Download Table
Back to Basics | NEJM
Treatment of Hypertension in Patients 80 Years of Age or Older | NEJM
The Safety of Inpatient Health Care | NEJM
Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes | NEJM
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine | NEJM
Treatment Strategy for Rifampin-Susceptible Tuberculosis | NEJM
Early Treatment with Pegylated Interferon Lambda for Covid-19 | NEJM
Neonatal Diagnosis and Treatment of Menkes Disease | NEJM
Monoclonal Gammopathy of Undetermined Significance | NEJM
Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension | NEJM
Tomorrow | NEJM
Polypill Strategy in Secondary Cardiovascular Prevention | NEJM
Head and Neck Cancer | NEJM
Sedation and Delirium in the Intensive Care Unit | NEJM
Treatment of Acute Lymphoblastic Leukemia | NEJM
The New England Journal of Medicine and NEJM Group partner with Wolters ...
Essential Thrombocythemia | NEJM
Multiple Myeloma | NEJM
Empagliflozin in Patients with Chronic Kidney Disease | NEJM
Assessment of Patients' Competence to Consent to Treatment | NEJM
NEJM - New England Journal of Medicine · Bibliothèque universitaire
Screening for Prostate Cancer | NEJM
Initial Treatment of Hypertension | NEJM
Cardiovascular Disease | NEJM
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM
The ClinicalTrials.gov Results Database — Update and Key Issues | NEJM
Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease | NEJM
Striving for Diversity in Research Studies | NEJM
Adaptive Designs for Clinical Trials | NEJM
Breast Cancer | NEJM
Book Review | NEJM
Case 30-2022: A Newborn Girl with Hypoglycemia | NEJM
Antibody-Mediated Encephalitis | NEJM
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer | NEJM
The Large Pharmaceutical Company Perspective | NEJM
10-Year Update on Study Results Submitted to ClinicalTrials.gov | NEJM
Lecanemab in Early Alzheimer’s Disease | NEJM
Imaging the Brain | NEJM
Flow chart of study selection. NEJM New England Journal of Medicine ...
The research design. NEJM stands for New England Journal of Medicine ...
This Week in the Journal | NEJM
Nejm 2012 Case 38 - 知乎
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 ...
Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial ...
Complete or Culprit-Only PCI in Older Patients with Myocardial ...
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast ...
Fractional Flow Reserve–Guided Multivessel Angioplasty in Myocardial ...
Neuropathological Features of Covid-19 | New England Journal of Medicine
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical ...
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 ...
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil ...
Health-Status Outcomes with Invasive or Conservative Care in Coronary ...
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic ...
Antidepressant Augmentation versus Switch in Treatment-Resistant ...
Stroke, Myocardial Infarction, and Pulmonary Embolism after Bivalent ...
Acetazolamide in Acute Decompensated Heart Failure with Volume Overload ...
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity ...
Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS ...
New Guidelines for Statistical Reporting | New England Journal of Medicine
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for ...
Spontaneous-Breathing Trials with Pressure-Support Ventilation or a T ...
Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial ...
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung ...
Early Restrictive or Liberal Fluid Management for Sepsis-Induced ...
A Genomic Strategy to Refine Prognosis in Early-Stage Non–Small-Cell ...
Percutaneous Revascularization for Ischemic Left Ventricular ...
Tips: How to Read the New England Journal of Medicine | GomerBlog
Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin ...
STEM trial results in the New England Journal of Medicine (NEJM) - Balt ...
Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for ...
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic ...
Abbreviations: Ann Intern Med, Annals of Internal Medicine; NEJM, New ...
New England Journal of Medicine on Ovid | Wolters Kluwer
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic ...
Drug-Review Deadlines and Safety Problems | New England Journal of Medicine
A Randomized Trial of Enteral Glutamine for Treatment of Burn Injuries ...
Book Review | New England Journal of Medicine
The New England Journal of Medicine
National citation patterns of NEJM, The Lancet, JAMA and The BMJ in the ...
Recent Advances in Surgery | New England Journal of Medicine
Medicare and Prescription Drugs | New England Journal of Medicine
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV ...
Postoperative Irradiation with or without Concomitant Chemotherapy for ...
Statistical Methods in the Journal | New England Journal of Medicine
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease ...
Safety of Magnetic Resonance Imaging in Patients with Cardiac Devices ...
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell ...
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer ...
Cancer and the General Practitioner | New England Journal of Medicine
Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer ...
Long-Term Outcome Associated with Early Repolarization on ...
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for ...
Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge ...
Evidence for Health Decision Making — Beyond Randomized, Controlled ...
Treatment of Gestational Diabetes Mellitus Diagnosed Early in Pregnancy ...
Latest New England Journal of Medicine (NEJM) Impact Factor 2024 - IR ...
Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia ...
New England Journal of Medicine (NEJM) Impact Factor - Journal Impact ...
Transforming Evidence Generation to Support Health and Health Care ...
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 ...
An FDA Viewpoint on Unique Considerations for Medical-Device Clinical ...
New England Journal Of Medicine Subscription – Total Magazines
The New England Journal of Medicine; Volume 19 (Paperback ...
This Week in the Journal | New England Journal of Medicine
如何下载NEJM(新英格兰医学期刊)数据库文献论文 - 知乎
